Lisata Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Justin Branham has filed a Schedule 13G, reporting beneficial ownership of 5.1% of Lisata Therapeutics, Inc. common stock.